Transferable priority vouchers for first-in-class drugs, with price conditions
Reward companies that deliver a genuinely new kind of cancer drug with a sellable voucher for faster review of another product, but only if they agree to fair pricing and global access.
Extend the US priority review voucher model (rare paediatric disease, tropical disease) to oncology first-in-class approvals that show substantial survival benefit, with two conditions attached: a price commitment (for example launch price below a value-based threshold set by an independent body) and a global access plan (tiered pricing or licensing to the Medicines Patent Pool for low- and middle-income countries). The voucher is transferable and has sold for around $100 million historically, so the reward is real but costs the public little. Regulators would need statutory authority; a pilot could run through an existing programme's criteria.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
Pages like this
not linked directly; found by shared links- IdeaLaunch prices indexed to the ESMO benefit scale, revisited when survival matures
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains, Prices and value.
- TermReal-Time Oncology Review (RTOR) and Assessment Aid
Shares Breakthrough Therapy / Priority Review / Priority Voucher, Accelerated approval.
- IdeaShorter exclusivity for later-in-class drugs without added benefit
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains, Prices and value.
- TermFast Track and RMAT designations
Shares Breakthrough Therapy / Priority Review / Priority Voucher, Accelerated approval.
- TermOrphan drug
Shares Breakthrough Therapy / Priority Review / Priority Voucher, Accelerated approval.
- IdeaSponsors deposit the confirmatory trial budget in escrow at accelerated approval
Shares Accelerated approval, Incentives reward me-too drugs and marginal gains.
- IdeaBundled episode payments for cancer care with bonuses for guideline concordance
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaExtra exclusivity for sponsors who run treatment-duration and de-escalation trials
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.